Glucagon-Like Peptide 1 Receptor Agonist Stimulation Inhibits Laser-Induced Choroidal Neovascularization by Suppressing Intraocular Inflammation
Liraglutide suppresses CNV formation, likely via NLRP3 inflammasome inhibition. Intraocular GLP-1R appears to mediate anti-CNV effects, supporting GLP-1R agonists as potential adjunctive therapy for exudative AMD and warranting further investigation into its safety and clinical feasibility.
Authors
- Sugao Miyagi (ORCID: https://orcid.org/0000-0001-5374-8213)
- Yuki Maekawa (ORCID: https://orcid.org/0000-0003-3026-1714)
- Ryuya Murakami
- T Nakayama (ORCID: https://orcid.org/0000-0003-4215-2865)
- Akira Machida (ORCID: https://orcid.org/0000-0002-1672-6792)
- Masafumi Uematsu (ORCID: https://orcid.org/0000-0002-9584-4323)
- Keiji Suzuki
- Akio Oishi (ORCID: https://orcid.org/0000-0002-0977-9458)
- Takashi Kitaoka
Institutions
- Inoue Hospital (JP)
- Nagasaki Medical Center (JP)
- Nagasaki University (JP)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1167/iovs.66.5.15
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41
Funders
- Kowa Company
- Santen
- Novartis Pharma
- Chugai Pharmaceutical
- Bayer Yakuhin
- Japan Society for the Promotion of Science